REGN5668
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | REGN5668 |
| Trade Name | |
| Synonyms | REGN 5668|REGN-5668 |
| Drug Descriptions |
REGN5668 is a bispecific monoclonal antibody that targets both CD28 and MUC16 (CA125), resulting in cross-linking of CD28-positive T-cells to MUC16-expressing tumor cells, potentially leading to enhanced cytotoxic response against MUC16-positive tumor cells (NCI Drug Dictionary). |
| DrugClasses | CD28 Antibody 12 MUC16 Targeted Therapy 10 |
| CAS Registry Number | NA |
| NCIT ID | C176028 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cemiplimab + Fianlimab + REGN5668 | Cemiplimab Fianlimab REGN5668 | 0 | 1 |
| Cemiplimab + REGN5668 | Cemiplimab REGN5668 | 0 | 1 |
| REGN5668 | REGN5668 | 0 | 1 |
| REGN5668 + Sarilumab + Ubamatamab | REGN5668 Sarilumab Ubamatamab | 0 | 1 |
| REGN5668 + Ubamatamab | REGN5668 Ubamatamab | 0 | 1 |
CKB BOOST